Access to Residential Addiction Treatment Centers for Teens Limited
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 9, 2024 -- For adolescents, access to U.S. residential addiction treatment centers is limited and costly, according to a study published in the January issue of Health Affairs.
Caroline A. King, M.P.H., from Oregon Health & Science University in Portland, and colleagues identified 160 residential addiction treatment facilities that treated adolescents with opioid use disorder as of December 2022 using the Substance Abuse and Mental Health Services Administration treatment locator and search engine advertising data. While role-playing the aunt or uncle of a 16-year-old child with a recent nonfatal overdose, facilities were called to ask about policies and costs.
The researchers found that 54.4 percent of the facilities had a bed available immediately. The mean wait time for a bed was 28.4 days among sites with a wait list. The mean cost of treatment per day was $878 among the facilities providing cost information. Daily costs were triple among for-profit versus nonprofit facilities. Up-front payment by self-pay patients was required by half of the facilities, with the mean upfront cost of $28,731. In 10 states and Washington, D.C., no facilities were identified for adolescents.
"Findings suggest that systems-level interventions are needed to ensure adequate, equitable access to affordable treatment, including for Medicaid patients and through both residential and outpatient treatment," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-10 00:15
Read more
- Men Aged >16 to
- Scientists Track Brain Function as Folks Watch Movies
- Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
- Liquor, Wine, Beer: Which Comes With the Worst Lifestyle?
- Want to Slowly Cut Down on Dietary Salt? Here's How
- Men Aged >16 to to <55 years at increased risk for acute kidney injury (AKI)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions